# Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

> **NCT01007942** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 569 (actual)

## Conditions studied

- HER2/Neu Over-expressing Locally Advanced Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** everolimus
- **DRUG:** Placebo
- **DRUG:** vinorelbine
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT01007942
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 569 (ACTUAL)
- **Last updated:** 2017-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01007942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01007942, "Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01007942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*